American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

CDC data highlights surge in obesity rates, driving demand for weight loss drugs

by admin September 13, 2024
September 13, 2024
CDC data highlights surge in obesity rates, driving demand for weight loss drugs

Recent data from the Centers for Disease Control and Prevention (CDC) underscores a dramatic shift in obesity trends across the US over the past decade.

The 2023 figures highlight a persistent and widespread obesity crisis, bolstering the market for weight loss drugs, where Eli Lilly and Novo Nordisk are currently the leading players.

Key findings from the CDC data

The CDC’s latest report reveals that every US state now has at least 20% of its adult population classified as obese.

Notably, 23 states have an obesity prevalence exceeding 35%, indicating that one in three adults in these regions could benefit from weight loss treatments.

Obesity is often linked to factors beyond diet, and the CDC emphasizes the urgent need for advanced treatment options.

According to Karen Hacker of the CDC, this data underscores the critical demand for effective obesity prevention and treatment strategies.

In response to the growing need, Novo Nordisk and Eli Lilly have emerged as leaders in the weight loss drug market.

Novo Nordisk’s Wegovy, a GLP-1 receptor agonist, and Eli Lilly’s Zepbound have been particularly successful.

Both companies have seen substantial revenue increases over the past year due to the high demand for their weight loss solutions.

Novo Nordisk vs. Eli Lilly

Novo Nordisk is expanding its portfolio with amycretin, a new drug that combines two peptide hormones in a single molecule.

This innovative approach aims to enhance appetite regulation and hunger control, offering a potential alternative to Wegovy.

In response to the high demand and supply constraints, Eli Lilly is investing $1.8 billion to boost its production capabilities for weight loss, Alzheimer’s, and diabetes medications.

The company is focusing on expanding its Kinsale, Ireland facility, with an additional $800 million investment to increase its manufacturing capacity.

UBS now expects the weight loss drug market to grow at a compound annualized rate of 33% and hit $150 billion in sales by 2029 – up from the firm’s earlier forecast of about $125 billion. 

The company has also achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. 

Novo Nordisk has also got approval for its weight-loss drug from China.

Both Novo Nordisk and Eli Lilly are well-positioned to capitalize on the ongoing obesity trend.

Despite current short-term supply issues potentially impacting stock performance, the long-term outlook for these companies remains strong.

Their advancements and expansions in the weight loss sector suggest promising medium-term investment opportunities.

The post CDC data highlights surge in obesity rates, driving demand for weight loss drugs appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Are Lloyds Bank, NatWest, and Barclays at risk from Revolut?
next post
Is Rivian truly ‘one or two programs away from bankruptcy’?

Related Posts

AT&T, other phone companies sued over stolen nude...

July 31, 2024

Vodafone share price rally has stalled: buy, sell,...

October 16, 2024

SNAP stock is troubled, but a major comeback...

December 7, 2024

Quantum Computing Inc.’s (QUBT) stock surged, but has...

November 14, 2024

The IRS’s new, free ‘Direct File’ service for...

February 28, 2024

Abortion bans drive away up to half of...

May 9, 2024

How China’s 34% tariff on US imports could...

April 5, 2025

Apple stock under pressure: Will AI glasses make...

May 23, 2025

Rolls-Royce stock jumps 15% as investors applaud financial...

February 27, 2025

The Fed’s preferred inflation measure rose 0.2% in...

June 2, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (3,002)
    • Investing (2,453)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved